$0.08
(Market cap
$1,392 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
13.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$-3.2
-
Face value
--
-
Shares outstanding
94,219,634
8 Years Aggregate
CFO
$-566.11 Mln
EBITDA
$-708.85 Mln
Net Profit
$-699.85 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Replimune Group (REPL)
| 63.4 | 63.7 | 223.4 | 189.3 | -8.2 | -12.6 | -- |
|
BSE Sensex*
| -8.6 | 1.7 | 1.8 | -4.2 | 6.0 | 6.7 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Replimune Group (REPL)
| -19.7 | 43.2 | -69.0 | 0.4 | -29.0 | 165.9 | 43.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Replimune Group (REPL)
|
15.9 | 1,391.6 | 0.0 | -297.0 | -- | -187.9 | -- | 13.2 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Replimune Group (REPL)
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic... immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts. Read more
-
Executive Chairman
Mr. Philip Astley-Sparke F.S.A.
-
Executive Chairman
Mr. Philip Astley-Sparke F.S.A.
-
Headquarters
Woburn, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Replimune Group (REPL)
What is the current share price of Replimune Group Inc (REPL) Today?
The share price of Replimune Group Inc (REPL) is $15.88 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Replimune Group Inc (REPL) has given a return of -8.23% in the last 3 years.
What is the current PB & PE ratio of Replimune Group Inc (REPL)?
Since, TTM earnings of Replimune Group Inc (REPL) is negative, P/E ratio is not available.
The P/B ratio of Replimune Group Inc (REPL) is 13.15 times as on 21-Aug-2026, a 146 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-2.26 |
4.27 |
2025 |
-3.18 |
1.89 |
2024 |
-2.33 |
1.34 |
2023 |
-5.74 |
1.80 |
2022 |
-6.81 |
1.95 |
What is the 52 Week High and Low of Replimune Group Inc (REPL)?
The 52-week high and low of Replimune Group Inc (REPL) are Rs 15.99 and Rs 1.50 as of 27-Aug-2026.
What is the market cap of Replimune Group Inc (REPL)?
Replimune Group Inc (REPL) has a market capitalisation of $ 1,392 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Replimune Group Inc (REPL)?
Before investing in Replimune Group Inc (REPL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.